Oteseconazole (VT-1161): Precision Antifungal for Candida Control

Executive Summary: Oteseconazole (VT-1161) is a tetrazole antifungal that selectively inhibits fungal CYP51, essential for ergosterol biosynthesis and membrane integrity (source: product_spec). It exhibits potent activity against multiple Candida species, including fluconazole-resistant strains, with MICs as low as 0.00625 μg/mL (source: paper). The compound demonstrates markedly reduced inhibition of human CYP enzymes, notably CYP3A4 (IC50 = 65 μM), reducing drug-drug interaction risk (source: product_spec). Clinical use includes oral therapy for recurrent vulvovaginal candidiasis, maintaining plasma concentrations above the MIC. Oteseconazole is provided by APExBIO as BA1665 for research applications.

Biological Rationale

Fungal infections caused by Candida species remain a significant clinical challenge, particularly in immunocompromised populations and in cases of recurrent vulvovaginal candidiasis (RVVC). Resistance to first-line azole antifungals such as fluconazole is increasing, necessitating the development of agents with novel selectivity and resistance profiles (source: paper). Oteseconazole targets the ergosterol biosynthesis pathway, critical for fungal viability, by binding and inhibiting the CYP51 enzyme (lanosterol 14α-demethylase). This pathway is unique to fungi, providing a selective therapeutic window with minimized human cell toxicity (source: internal).

Mechanism of Action of Oteseconazole (VT-1161)

Oteseconazole is a potent, selective tetrazole inhibitor of fungal CYP51. The enzyme CYP51 catalyzes a key demethylation step in the conversion of lanosterol to ergosterol, necessary for fungal cell membrane structure and function. By binding tightly to the fungal isoform of CYP51, Oteseconazole disrupts ergosterol production, compromising membrane integrity and inhibiting cell growth (source: product_spec). Structural studies indicate that Oteseconazole's tetrazole ring enhances selectivity for the fungal enzyme over human CYPs, particularly CYP3A4, reducing off-target effects (source: internal). This selectivity is evidenced by a >500-fold difference in IC50 values for fungal versus human CYP51.

Evidence & Benchmarks

• Oteseconazole inhibits Candida albicans growth at MICs as low as 0.00625 μg/mL under microbroth dilution conditions (source: paper).
• Demonstrates activity against Candida tropicalis, C. parapsilosis, C. glabrata, C. krusei, and Cryptococcus neoformans, with reported MICs ≤0.1 μg/mL (source: product_spec).
• Exhibits minimal inhibition of human CYP3A4 (IC50 = 65 μM), reducing risk of drug-drug interactions compared to triazole antifungals (source: product_spec).
• Inactive against Aspergillus fumigatus (MIC >64 μg/mL), indicating a narrow antifungal spectrum (source: product_spec).
• Retains efficacy against fluconazole-resistant Candida isolates, supporting use in azole-resistant infections (source: internal).
• Solubility in DMSO and ethanol (≥50 mg/mL), but insoluble in water; recommended storage at -20°C for stability (source: product_spec).
• Clinical dosing aims to maintain plasma concentrations above the MIC for prevention of RVVC (source: product_spec).

Oteseconazole (VT-1161): Selective Tetrazole CYP51 Inhibitor provides foundational details on selectivity, which this article extends by summarizing new clinical and resistance data. For mechanistic depth, see Mechanistic Precision in Antifungal Targeting, clarified here with updated pharmacodynamic benchmarks. Comparative perspectives on resistance management are further explored in Next-Generation Antifungal Targeting, while this article provides explicit protocol and cross-species activity data.

Applications, Limits & Misconceptions

Oteseconazole is indicated for the prevention of recurrent vulvovaginal candidiasis, especially where fluconazole resistance is present or anticipated. Its high selectivity supports use in patients with polypharmacy, lowering the risk of adverse drug interactions. However, the antifungal spectrum is limited; it is not active against Aspergillus species or bacterial pathogens (source: product_spec). The compound is best suited for Candida-focused applications, both in clinical and research contexts.

Common Pitfalls or Misconceptions

• Not Broad-Spectrum: Oteseconazole is inactive against molds such as Aspergillus fumigatus and should not be used for these infections (source: product_spec).
• Solubility Constraints: Insoluble in water; must be dissolved in DMSO or ethanol for in vitro applications (source: product_spec).
• Not a General Antibacterial: No activity against bacterial species; misapplication in bacterial infections is ineffective (source: paper).
• Stability Concerns: Prepared solutions are recommended for short-term use only and should be stored at -20°C to maintain stability (source: product_spec).
• Human CYP Inhibition: While selectivity is high, minimal inhibition of human CYP enzymes can occur at supra-therapeutic concentrations (source: product_spec).

Workflow Integration & Parameters

Protocol Parameters

• assay: microbroth dilution | value_with_unit: 0.00625–0.1 μg/mL | applicability: in vitro Candida susceptibility testing | rationale: established MIC range for Candida strains | source_type: paper (link)
• assay: human CYP3A4 inhibition | value_with_unit: IC50 = 65 μM | applicability: drug interaction risk assessment | rationale: benchmark for selectivity over human enzymes | source_type: product_spec (link)
• assay: solubility | value_with_unit: ≥50 mg/mL in DMSO/ethanol | applicability: stock preparation for assays | rationale: ensures adequate compound delivery | source_type: product_spec (link)
• assay: solution stability | value_with_unit: store at -20°C, use short-term | applicability: working solution maintenance | rationale: preserves compound integrity | source_type: workflow_recommendation
• assay: clinical dosing | value_with_unit: maintain plasma >MIC | applicability: RVVC prevention | rationale: ensures efficacy against recurrent infection | source_type: product_spec (link)

Conclusion & Outlook

Oteseconazole (VT-1161) represents a significant advance in selective antifungal therapy for Candida infections, particularly in the context of rising azole resistance. Its narrow but potent spectrum, excellent selectivity for fungal CYP51, and favorable safety profile make it a preferred choice for recurrent vulvovaginal candidiasis and research on Candida pathogenesis (source: product_spec). Future directions include further clinical validation in resistant populations and expanded exploration of combination therapies within the Candida genus, as supported by current in vitro and clinical evidence (source: paper).